Description:
Approved for treating Duchenne muscular dystrophy.

Text:
Furthermore, 
inhibition of HDACs promotes apoptosis and enhances cell differentiation.6,9 U.S. Food and Drug 
Administration (FDA) or European Medicines Agency (EMA) approved HDACi, such as vorinostat, 
belinostat, and romidepsin, for the treatment of Tcell lymphoma, panobinostat for the 
treatment of multiple myeloma, and givinostat for treating Duchenne muscular dystrophy.10,11 
httpsdoi.org10.26434chemrxiv2025bdnwmv2 ORCID httpsorcid.org0000000197655975 Content not peerreviewed by ChemRxiv. License CC BY 4.0
